Pompe Disease Clinical Landscape Report 2026: Trials, Readouts and White Space
Turn fragmented clinical intelligence into a decision-ready landscape. This report was assembled with PatSnap MCP Servers for Clinical Trials, Drug & Asset, and Company & Deal Intelligence. Explore the PatSnap MCP Marketplace to reproduce the workflow in your own AI research stack.
Data snapshot: 16 July 2026. This report is a strategic research view, not medical advice. Trial status and timing can change; confirm records before making development or investment decisions.
Executive view
Pompe Disease remains an active clinical development field. One-time and precision therapies are raising the efficacy ceiling, but durability, manufacturing, small-population evidence and long-term safety remain decisive constraints. The PatSnap evidence set used here contains 100 matched trial records and 84 indexed result records before the decision-focused sample below was selected.
How PatSnap MCP built this report
The workflow used Clinical Trials MCP search to define the landscape, then clinical_trial_fetch to retrieve trial design, phase, status, sponsor, geography, endpoints and timing. It separately called clinical_trial_result_fetch for indexed readouts. Drug & Asset drug_fetch supplied target and global development status, while Company & Deal Intelligence organization_fetch supplied sponsor context. This keeps trial-, asset- and company-level claims distinct and traceable.
Trial landscape table
| Trial | Asset / intervention | Phase / status | Sponsor | Geography | Primary endpoint | Expected readout |
|---|---|---|---|---|---|---|
| NCT07700147 | Intervention not normalized | Not Applicable; Not yet recruiting | Nu Eyne Co. Ltd. | South Korea | Change in Best Corrected Visual Acuity (BCVA) Measured by ETDRS Letter Score (Baseline, Week 2, Week 6, Week 12, Week 16); Change in Contrast Sensitivity (Baseline, Week 2, Week 6, Week 12, Week 16) | 2027-12-09 |
| NCT07664930 | Intervention not normalized | Not Applicable; Recruiting | IRCCS National Neurological Institute C. Mondino Foundation | Italy | Motor latency (ms) (Baseline (at first available assessment, retrospective or prospective)); Compound muscle action potential (CMAP) amplitude (millivolts) (Baseline (at first available assessment, retrospective or prospective)) | 2029-02-28 |
| NCT07652814 | Avalglucosidase alfa | Phase 4; Active, not recruiting | Sponsor not listed | Netherlands | Incidence/occurrence of adverse events (From enrollment to the end of study duration at 5 years); The occurence of antibodies against avalglucosidase alfa (From enrollment to the end of study duration at 5 years) | 2028-03-09 |
| JPRN-jRCT2071260009 | Pegcetacoplan + Geographic Atrophy (Clearside) + Gambogic acid | Phase 3; 募集前 | Apellis Pharmaceuticals, Inc. | Japan | AMDに伴うGAを有する日本人被験者を対象に、pegcetacoplanをIVT投与したときの安全性及び忍容性を評価する ・TEAE（治験薬投与後に発現した有害事象）及び重篤なTEAEの発現率及び重症度; To assess the safety and tolerability of pegcetacoplan administered IVT in Japanese participants with GA secondary to AMD - incidence and severity of TEAEs (treatment-emergent adverse event) and serious TEAEs | 2028-05-31 |
The table is designed for competitive decisions: endpoint selection, geographic reach and readout timing appear beside phase and sponsor. Phase alone does not reveal evidence maturity; a small study may answer a near-term biomarker question while a large pivotal program can leave a multi-year readout gap.
What indexed results say
- Aro Biotherapeutics Reports Positive Phase 1b Topline Results for ABX1100, a Muscle-targeted GYS1 siRNA, in Patients with Late-Onset Pompe Disease (LOPD) (Phase 1): the indexed record reports GYS1 mRNA knockdown(Week 10) = - 62.0 %.
- Update on FORTIS: A phase 1/2 open-label clinical trial on AT845 gene replacement therapy for late-onset Pompe disease (Phase 1/2): the indexed record reports 6MWD(48 weeks) = −0.19 % predicted ( −0.9 - 0.5).
- 90-month pulmonary function outcomes with cipaglucosidase alfa+miglustat in adults with Pompe disease in ATB200-02, an open-label phase I/II study (Phase 1/2): the indexed record reports ppFVC(month 60) = 5.0 % ( 8.07); -.
Cross-trial comparisons require caution. Population, prior therapy, baseline risk, endpoint definition, follow-up and analysis set can all change the apparent signal. The strategic value lies in identifying what each readout resolves—and which uncertainty remains.
Build a living clinical map: connect to PatSnap MCP Servers and combine trial design, result, asset and organization records without manually reconciling separate databases.
Asset and sponsor context
PatSnap Drug & Asset records add mechanism and global development status for the sampled programs, including Avalglucosidase alfa (Approved; M6PR x α-glucosidase), Pegcetacoplan (Approved; C3), Geographic Atrophy (Clearside) (Preclinical), Gambogic acid (Preclinical; HSP90 x Tubulin). Company & Deal Intelligence records identify sponsor context for Nu Eyne Co. Ltd., IRCCS National Neurological Institute C. Mondino Foundation, Apellis Pharmaceuticals, Inc. (APLS). Together, those layers show whether a study sits inside a scaled portfolio, an emerging specialist strategy or an academic development path.
Where the white space is
- Natural-history-aligned endpoints that remain interpretable in small heterogeneous cohorts.
- Long-term registries for durability, immunogenicity and delayed safety signals.
- Redosing, rescue and treatment-sequencing strategies after incomplete response.
- Access models that address diagnosis, manufacturing and global delivery.
Strategic implications
For sponsors, differentiation is more credible when the evidence package resolves a known decision gap: an active comparator, a better-defined responder population, a safer or easier delivery model, a clinically meaningful outcome, or a defensible sequencing strategy. Business-development teams can use the same landscape to separate crowded mechanisms from differentiated evidence architectures. Investors should track endpoint maturity and operational feasibility alongside nominal phase.
What to monitor next
Track status changes, protocol amendments, primary-completion dates, newly indexed results, ownership changes and multinational expansion. Re-run the MCP queries on a schedule and compare deltas. Pay particular attention when a program moves from a surrogate endpoint to a clinical outcome or when a specialist sponsor adds a scaled development partner.
Bottom line
Pompe Disease has meaningful clinical activity and equally meaningful evidence gaps. A useful landscape connects trial design, results, mechanism and sponsor rather than listing studies in isolation.
Ready to reproduce this analysis? Explore PatSnap MCP Servers and use Clinical Trials, Drug & Asset, and Company & Deal Intelligence as structured building blocks for monitoring and SEO-ready clinical reports.
